Synopsis A clinical study demonstrates a significant clinical advantage for sacubitril/valsartan versus enalapril, an angiotensin-converting enzyme (ACE) inhibitor in patients with heart failure with reduced ejection fraction. This week's ' 'MED FACT'' discusses a clinical trial from International Journal Of Cardiology, “ Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study ” . 2018. Authors : Victor Shi et.
al. Key Takeaways After administration of sacubitril/valsartan versus enalapril therapy, the angioedema events were found out to be low with no noticeable risk of angioedema. Objective Study Type Participants To study Angioedema in patients treated with sacubitril/valsartan versus enalapril Randomized, Double-Blind, Multinational Study 10,513 What Was The Need For This Study? Sacubitril/valsartan were found out…
